Individuals with severe injuries to their extremities often develop abnormal extra-skeletal bone in damaged or healing tissue, known as heterotopic ossification (HO). This post-traumatic abnormal wound healing can interfere with recovery, causing chronic pain, reduced mobility, and impaired prosthetic limb function. Rapamycin, an FDA-approved drug already on the market, was found to dramatically reduce the presence of HO in rats, suggesting it has potential to become the first effective treatment to prevent HO.
This post was syndicated from Top Health News -- ScienceDaily. Click here to read the full text on the original website.